Stockscreener 앱 받기
35.36
0.03%
0.0395
전일 마감가:
$35.32
열려 있는:
$35.14
하루 거래량:
713.97K
Relative Volume:
0.19
시가총액:
$3.99B
수익:
-
순이익/손실:
$-99.15M
주가수익비율:
-38.02
EPS:
-0.93
순현금흐름:
$-74.25M
1주 성능:
-5.41%
1개월 성능:
-4.02%
6개월 성능:
+33.32%
1년 성능:
-12.20%
1일 변동 폭
$34.67
$35.40
1주일 범위
$34.67
$37.44
52주 변동 폭
$18.92
$43.55
Viking Therapeutics Inc Stock (VKTX) Company Profile
명칭
Viking Therapeutics Inc
전화
858-704-4660
주소
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
VKTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
35.32 | 3.99B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.67 | 115.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.57 | 81.34B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.44 | 52.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
838.87 | 51.59B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.59 | 37.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-29 | 개시 | Canaccord Genuity | Buy |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-08 | 개시 | Goldman | Neutral |
| 2025-02-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-07 | 개시 | Citigroup | Neutral |
| 2024-12-02 | 개시 | Piper Sandler | Overweight |
| 2024-11-22 | 개시 | B. Riley Securities | Buy |
| 2024-11-04 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-11 | 개시 | JP Morgan | Overweight |
| 2024-06-27 | 개시 | Morgan Stanley | Overweight |
| 2024-05-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | 재확인 | Oppenheimer | Outperform |
| 2024-03-07 | 개시 | Jefferies | Buy |
| 2024-02-28 | 재확인 | Oppenheimer | Outperform |
| 2023-05-31 | 재개 | ROTH MKM | Buy |
| 2023-03-28 | 재확인 | Maxim Group | Buy |
| 2023-03-17 | 개시 | Stifel | Buy |
| 2021-07-29 | 재개 | BTIG Research | Buy |
| 2021-05-25 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | 개시 | BMO Capital Markets | Outperform |
| 2020-05-05 | 개시 | Chardan Capital Markets | Buy |
| 2020-05-01 | 개시 | BTIG Research | Buy |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-25 | 개시 | Stifel | Buy |
| 2019-03-29 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | 재확인 | Maxim Group | Buy |
| 2019-02-22 | 개시 | SVB Leerink | Mkt Perform |
| 2018-12-12 | 개시 | B. Riley FBR | Buy |
| 2018-11-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2018-09-18 | 재확인 | Maxim Group | Buy |
| 2018-09-18 | 재확인 | Raymond James | Outperform |
| 2018-07-20 | 개시 | SunTrust | Buy |
| 2018-06-28 | 개시 | Raymond James | Outperform |
| 2018-06-01 | 재확인 | Laidlaw | Buy |
| 2018-05-31 | 재확인 | Maxim Group | Buy |
| 2018-03-26 | 재개 | H.C. Wainwright | Buy |
| 2017-11-28 | 재확인 | Maxim Group | Buy |
| 2017-11-21 | 개시 | ROTH Capital | Buy |
모두보기
Viking Therapeutics Inc 주식(VKTX)의 최신 뉴스
2 Beaten-Down Stocks That Could Bounce Back in 2026 - The Globe and Mail
Viking Therapeutics: A High-Stakes Investment at a Critical Juncture - AD HOC NEWS
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Viking Therapeutics Shares Face Mounting Pressure - AD HOC NEWS
Insider Selling and Clinical Progress Shape Viking Therapeutics’ Stock Trajectory - AD HOC NEWS
Harbor Capital Advisors Inc. Trims Stock Holdings in Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics: Investors Eye Pivotal Phase 3 Catalyst - AD HOC NEWS
Viking Therapeutics' Swing Trade Potential EmergesCompetition/Dilution Risks Remain (NASDAQ:VKTX) - Seeking Alpha
Price Action: Is Viking Therapeutics Inc. stock a good choice for value investorsMarket Volume Report & Real-Time Sentiment Analysis - moha.gov.vn
Viking Therapeutics, Inc. (VKTX) beats stock market upswing: What investors need to know - MSN
Market Moves: Is Viking Therapeutics Inc. stock a good choice for value investorsJuly 2025 Market Mood & Growth Focused Entry Reports - moha.gov.vn
Could Viking Therapeutics Become the Next Eli Lilly? - AOL.com
Why This Beaten-Down GLP-1 Stock Could Be a Steal - AOL.com
Here's How Much $100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today - Sahm
Viking Therapeutics (VKTX) Is Up 8.9% After Rival Data Bolsters Its Oral Obesity Program - Yahoo Finance
Wall Street bulls look optimistic about Viking Therapeutics (VKTX): Should you buy? - MSN
Viking Therapeutics (VKTX): Revisiting Valuation After a Renewed Share Price Rally - simplywall.st
Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know - sharewise.com
Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy? - Finviz
(VKTX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Viking Therapeutics Earnings Notes - Trefis
The Bull Case For Viking Therapeutics (VKTX) Could Change Following Fresh Validation Of Oral Obesity Drugs - simplywall.st
Viking Therapeutics, Inc. (NASDAQ:VKTX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
How to Buy Viking Therapeutics Stock (VKTX) - The Motley Fool
U.S. Capital Wealth Advisors LLC Buys 30,619 Shares of Viking Therapeutics, Inc. $VKTX - MarketBeat
Here is Why H.C. Wainwright Sees Immense Upside for Viking Therapeutics (VKTX) - Finviz
Profit Investment Management LLC Decreases Stock Position in Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts - MSN
Viking Therapeutics Stock Gains on Analyst Confidence and Pipeline Progress - AD HOC NEWS
Viking Therapeutics, Inc. (VKTX): A bull case theory - MSN
Published on: 2025-12-20 09:00:30 - ulpravda.ru
Analyst Confidence Fuels Viking Therapeutics Stock Rebound - AD HOC NEWS
Viking Therapeutics Inc. (VKTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Viking Therapeutics: A Stock Poised Between High Conviction and High Short Interest - AD HOC NEWS
Chipmakers Recap: Is Viking Therapeutics Inc. stock a good choice for value investorsQuarterly Portfolio Report & Free Reliable Trade Execution Plans - Улправда
Viking Therapeutics Faces Intensifying Market Competition - AD HOC NEWS
Eli Lilly’s oral obesity drug passes maintenance test after Wegovy, Zepbound — Wall Street flags win for Viking Therapeutics - MSN
Analyst Confidence Soars for Viking Therapeutics with $102 Price Target - AD HOC NEWS
Why Viking Therapeutics Inc. stock remains undervaluedDividend Hike & Accurate Trade Setup Notifications - Улправда
Viking Therapeutics, Inc. (VKTX): A Bull Case Theory - Finviz
Eli Lilly’s Oral Obesity Drug Passes Maintenance Test After Wegovy, Zepbound — Wall Street Flags Win For Viking Therapeutics - Stocktwits
Viking Therapeutics: External Validation and Same-Molecule Strategy De-Risk Obesity Program, Supporting Buy Rating - TipRanks
Viking Therapeutics Stock Faces Technical Headwinds Despite Clinical Progress - AD HOC NEWS
Viking Therapeutics (VKTX): Assessing an Expensive Valuation After a Recent Pullback in the Share Price - simplywall.st
Viking Therapeutics (VKTX): Rethinking Valuation After a Sharp Pullback and Strong Multi‑Year Run - Yahoo Finance
1 Bold Prediction for Viking Therapeutics in 2026 - sharewise.com
1 bold prediction for Viking Therapeutics in 2026 - MSN
Viking Therapeutics (VKTX) deemed 'extremely attractive' and undervalued by Canaccord, cited as leader in obesity clinical development - MSN
2 Monster Stocks in the Making to Buy and Hold - AOL.com
Viking Therapeutics, Inc. (VKTX) registers a bigger fall than the market: Important facts to note - MSN
2 Monster Stocks in the Making - MSN
Viking Therapeutics Inc (VKTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Viking Therapeutics Inc 주식 (VKTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Rowland Charles A Jr | Director |
Oct 27 '25 |
Sale |
35.57 |
60,000 |
2,134,278 |
30,000 |
| Lian Brian | President & CEO |
Oct 28 '25 |
Sale |
35.01 |
38,989 |
1,364,923 |
2,419,109 |
| ZANTE GREG | Chief Financial Officer |
Oct 28 '25 |
Sale |
35.00 |
6,185 |
216,481 |
173,592 |
0.27%
0.34%
자본화:
|
볼륨(24시간):